Author

Julia X. Chen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Organism:E. coli· 1

Frequent Co-Authors

Bruce T. LahniD· 3 shared Cole K. ZhengiD· 3 shared Jack F. Hong· 3 shared Jason Z. YeiD· 3 shared Silk J. Shi· 3 shared Amy Y. CheniD· 2 shared Austin T. GaoiD· 2 shared Chinnuwat SanguansermsriiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenetic & Genomic Medicine

Bruce T. LahnORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Twelve-Month Outcomes of Intrathecal Vesemnogene Lantuparvovec for Spinal Muscular Atrophy in Children Younger than 24 Months in Low- and Middle- Income Countries

Lock Hock Ngu, Qingling Mo, Shiqi Li, Tsun-Haw Toh, Jia Ni Lee, Kok Chong Lim, Edi Setiawan Tehuteru, Rahmi Lestari, Chinnuwat Sanguansermsri, Hany Abueita, Samson Gwer, Li Li, Zhuowei Wang, Salman Kirmani, Julia X. Chen, , Austin T. Gao

This study evaluates the 12-month outcomes of vesemnogene lantuparvovec, an intrathecal gene therapy for SMA in children under 24 months in LMICs, showing safety and motor milestone improvements.

medRxiv · May 30, 2026 · PreprintGenetic & Genomic Medicine

miniVec: A miniaturized plasmid backbone supporting antibiotic-free and additive-free fermentation with enhanced yield and functionality

Silk J. Shi, Yingjun Lin, Jason Z. Ye, A Kwok, Kyrie Z. Want, Jesse Z. Cai, Mina M. Hu, Arianna Y. Liu, Kyler J. Li, Bernice Y. Guo, Herman H. Xia, Evian P. Huang, Julia X. Chen, Jack F. Hong, Cole K. Zheng, Bruce T. Lahn

miniVec is a new plasmid backbone that eliminates antibiotic resistance genes and improves plasmid yield and functionality for clinical applications.

bioRxiv · Oct 2, 2025 · PreprintBioengineering

Safety and Efficacy of Vesemnogene Lantuparvovec, an AAV-Based Gene Therapy in Young Children Under 24 Months with Spinal Muscular Atrophy in Low- and-Middle- Income Countries. Second Interim Report (August 2025).

This paper reports on a phase 1 trial of vesemnogene lantuparvovec, an affordable gene therapy for SMA, showing safety and improved motor milestones in young children.

medRxiv · Apr 13, 2025 · PreprintGenetic & Genomic Medicine